Systemic hormone therapy should be reassessed annually.

Systemic hormone therapy should be reassessed annually.

• A. True
• B. False
• C. Only after 2 years
• D. Never

Answer: (A)

Systemic hormone therapy should be reviewed every year to ensure its ongoing benefits still outweigh any risks and to adjust treatment as the woman's health and symptoms evolve. Reassessment allows checking how well symptoms are controlled, monitoring for adverse effects (such as breast changes, cardiovascular risks, or thromboembolism), and deciding whether to continue, reduce, pause, or stop therapy, or switch to alternatives. Since risk factors and medical conditions can change with time, an annual check keeps the plan aligned with the current situation.

Systemic hormone therapy should be reviewed every year to ensure its ongoing benefits still outweigh any risks and to adjust treatment as the woman's health and symptoms evolve. Reassessment allows checking how well symptoms are controlled, monitoring for adverse effects (such as breast changes, cardiovascular risks, or thromboembolism), and deciding whether to continue, reduce, pause, or stop therapy, or switch to alternatives. Since risk factors and medical conditions can change with time, an annual check keeps the plan aligned with the current situation.